Alembic Pharmaceuticals receives USFDA final approval for Lamotrigine Extended-Release Tablets
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Lacosamide is indicated to treat partial-onset seizures
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Granules now has a total of 58 ANDA approvals from US FDA
Acetazolamide is used to treat glaucoma
Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Subscribe To Our Newsletter & Stay Updated